Phio Pharmaceuticals (PHIO) risk factors
Item 1A of every Phio Pharmaceuticals Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors27 risks5 new5 dropped10 reworded
Phio Pharmaceuticals emphasizes risks regarding capital requirements, Nasdaq minimum bid compliance, and third-party manufacturing dependencies for its drug candidates.
Filed Mar 05, 2026 - FY2024 10-K risk factors27 risks
Phio is entirely dependent on its unproven INTASYL technology platform and early-stage product candidates for future revenue. The company faces ongoing financial losses, needs substantial additional capital, and risks Nasdaq delisting if equity falls below $2.5 million. Reliance on third parties for clinical trials, manufacturing, and intellectual property protection creates severe operational vulnerabilities.
Filed Mar 31, 2025